Vic biomeds dominate BIF round funding
20 March, 2002 by Pete YoungBiomedicine companies emerged the big winners among 22 biotech hopefuls who will share $4.74 million in the latest round of Biotechnology Innovation Fund grants.
Iatia IPO closes early after big demand
20 March, 2002 by Tanya HollisOptical technologies group Iatia has closed its initial public offering two days early after successfully raising $5 million to assist its commercialisation program.
Opinion: Necessary liaisons
19 March, 2002 by Debra GoldfarbOne of the extraordinary aspects of the Bio-IT market is the notion of "scale": the scale of scientific discovery, and the possibilities derived from discovery; the scale of growth, which requires looking at multiple dimensions such as the number of biotech companies, VC investments, IT infrastructure build-out, etcetera; and the scale of complexity, by which I mean the elaborate organisational ecosystems emerging in this market.
Sydney investor grabs a $3m stake in Melbourne
18 March, 2002 by Tanya HollisA Sydney investment fund has moved to grab a stake in Melbourne bioscience commercialisation group Biocomm Services, cementing its exposure to emerging Victorian biotechnology firms.
Vic ethics committee will examine biotech
15 March, 2002 by Tanya HollisA voluntary code of ethics for the Victorian biotechnology industry was likely to be the first task of the State Government's new ethics advisory committee.
Baker and Amersham establish proteomics system
15 March, 2002 by Iain ScottA fully-automated proteomics system has been installed at Melbourne's Baker Medical Research Institute.
Axon R&D push eats up profits
13 March, 2002 by Tanya HollisAn accelerated research program helped Aussie export Axon Instruments (ASX:AXN) drive sales up 25 per cent last year, but also contributed to a significant profit slump.
Eiffel restructuring leads to modest half-year
13 March, 2002 by Tanya HollisBioengineering group Eiffel Technologies (ASX: EIF) has posted a more than three per cent fall in after-tax profits to $777,000 for the second half of last year.
Biotechs may find VC funding hard to get
11 March, 2002 by Salvatore SalamoneBioinformatics, biotech and nanotechnology companies seeking venture capital funding may have to look elsewhere, according to speakers at the Silicon Alley Breakfast Club (SABC) meeting held in New York last week (March 7).
Group to assess platform tech needs
11 March, 2002 by Tanya HollisA government committee set up to assess Victoria's platform technology needs is expected to report its findings by mid-year.
Mixed results for Vita Life Sciences
08 March, 2002 by Tanya HollisBiopharmaceutical manufacturer and distributor Vita Life Sciences (ASX:VLS) posted a full-year revenue drop today because of a reduced sales forecast in its key Asian markets.
Micromedical's one-day fundraising spree
08 March, 2002 by Tanya HollisArtificial heart company MicroMedical Industries raised almost $11 million in just over 24 hours through a share placement directed at new investors.
Launched: the guide to avoiding ethical debate
08 March, 2002 by Tanya HollisA handbook to help clarify the decision-making process of research ethics committees was today launched by the Federal Health and Ageing Minister.
Networking event for young biotech
08 March, 2002 by Iain ScottA new group within industry association AusBiotech is about to host its first networking event.
Fenner, innovators honoured
08 March, 2002 by Tanya HollisWorld-renowned microbiologist Prof Frank Fenner was last night (March 7) honoured with a prestigious lifetime contribution award from the Ian Clunies Ross Memorial Foundation.
